WallStSmart

The Ensign Group Inc (ENSG)vsFresenius Medical Care Corporation (FMS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 272% more annual revenue ($19.63B vs $5.27B). ENSG leads profitability with a 6.9% profit margin vs 5.0%. FMS appears more attractively valued with a PEG of 0.75. FMS earns a higher WallStSmart Score of 62/100 (C+).

ENSG

Buy

60

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 4.7Quality: 6.3
Piotroski: 6/9Altman Z: 2.34

FMS

Buy

62

out of 100

Grade: C+

Growth: 5.3Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSGFair Value (-4.1%)

Margin of Safety

-4.1%

Fair Value

$203.60

Current Price

$182.03

$21.57 premium

UndervaluedFair: $203.60Overvalued
FMSUndervalued (+76.3%)

Margin of Safety

+76.3%

Fair Value

$101.44

Current Price

$20.19

$81.25 discount

UndervaluedFair: $101.44Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSG2 strengths · Avg: 8.0/10
Revenue GrowthGrowth
18.4%8/10

18.4% revenue growth

EPS GrowthGrowth
21.9%8/10

Earnings expanding 21.9% YoY

FMS4 strengths · Avg: 9.5/10
P/E RatioValuation
11.4x10/10

Attractively priced relative to earnings

Price/BookValuation
0.7x10/10

Reasonable price relative to book value

EPS GrowthGrowth
420.0%10/10

Earnings expanding 420.0% YoY

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Areas to Watch

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.634/10

Expensive relative to growth rate

P/E RatioValuation
30.0x4/10

Moderate valuation

Profit MarginProfitability
6.9%3/10

6.9% margin — thin

FMS4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
7.9%3/10

ROE of 7.9% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

Revenue GrowthGrowth
-0.3%2/10

Revenue declined 0.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth, EPS Growth. Revenue growth of 18.4% demonstrates continued momentum.

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, EPS Growth. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Bear Case : FMS

The primary concerns for FMS are Altman Z-Score, Return on Equity, Profit Margin. Thin 5.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

ENSG profiles as a growth stock while FMS is a value play — different risk/reward profiles.

FMS carries more volatility with a beta of 0.82 — expect wider price swings.

ENSG is growing revenue faster at 18.4% — sustainability is the question.

FMS generates stronger free cash flow (564M), providing more financial flexibility.

Bottom Line

FMS scores higher overall (62/100 vs 60/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Want to dig deeper into these stocks?